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Abstract 
Background: Anemia is frequent during HIV infection and is predictive of mortality. Although cART has demon‑
strated to reduce its prevalence, several patients still experience unresolved anemia. We aimed to characterize iron 
homeostasis and inflammation in HIV‑infected individuals with mild anemia in relation to cART.
Methods: In this retrospective cohort study, HIV‑infected patients with mild anemia,  CD4+ cells > 200/mm3 at 
baseline, maintaining virological response for 12 months after cART starting were selected within the Standardized 
Management of Antiretroviral Therapy Cohort (MASTER) cohort. Several inflammation and immune activation markers 
and iron homeostasis indexes were measured in stored samples, obtained at cART initiation (T0) and 12 months later 
(T1). Patients were grouped on the basis of hemoglobin values at T1: group A (> 13 g/dl) and B (< 13 g/dl). Wilcoxon 
rank sum test was used to compare biomarker values. Pearson correlation coefficients were calculated for all variables.
Results: cART improved  CD4+ and  CD8+ cell counts and their ratio, but this effect was significant only in group A. 
Only these patients had mild iron deficiency at T0 and showed higher transferrin and lower percentage of transfer‑
rin saturation than patients of group B, but differences disappeared with cART. cART decreased inflammation in all 
patients, but group B had higher levels of all markers than group A, reaching statistical significance only for IL‑8 values 
at T1 (16 vs 2.9 pg/ml; p = 0.017). Hepcidin and IL‑6 levels did not show significant differences between groups. 
Hemoglobin levels both at T0 and T1 did not correlate with any marker.
Conclusions: Baseline mild anemia in HIV‑infected patients cannot always be resolved with durable efficient cART, 
possibly due to residual inflammation or immune activation rather than unbalanced iron homeostasis. Further 
research is needed on cytokine profiling to understand the mechanisms that induce anemia in HIV with suppressive 
cART.
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Background
Chronic inflammation contributes to the development 
of anemia in both general population [1, 2] and human 
immunodeficiency virus (HIV)-infected people [3, 4]. 
Anemia is the most common haematological abnormality 
in HIV seropositive patients and is predictive of HIV-
associated morbidity and mortality, independently of 
 CD4+ count [4–10].
Anemia in HIV infection is a complex mechanism. HIV 
itself produces chronic immune activation and inflam-
mation and, under this inflammatory conditions, dietary 
iron is blocked from enterocyte release, whereas cir-
culating iron is redistributed into cellular storage loca-
tions including macrophages. Additional HIV-associated 
consequences, including suppression of several hemat-
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inflammation further contribute to anemia during HIV 
infection. Although combination anti-retroviral therapy 
(cART) has demonstrated to reduce the prevalence of 
anemia in many HIV-infected patients, a considerable 
proportion of those patients experiences unresolved ane-
mia or develop anemia after its initiation [12, 13]. Many 
studies have focused on the impact of cART on inflam-
mation and immune activation markers [3, 12], but there 
are few prospective studies dealing with the association 
between anemia, iron metabolism and inflammation 
markers in HIV-infected individuals before and after 
cART [14].
The pathophysiology of anemia during infections is 
multifactorial, resulting from the effects of inflamma-
tory cytokines, such as IL-6 and possibly other cytokines 
involved in host defense and leading to hepcidin-induced 
hypoferremia. The pro-inflammatory cytokine IL-6 is 
a dominant regulator of hepatic hepcidin production in 
bacterial infections and other inflammatory conditions, 
but IL-6 concentrations are often only mildly elevated in 
viral infections. Data on hepcidin levels in HIV infected 
patients are rarely reported [15–21].
Alterations of iron homeostasis are common in chronic 
inflammatory and infectious diseases [22]. In fact, preva-
lence of anemia among HIV-infected patients is high [3, 
6] and it is frequently resolved after cART initiation [23, 
24]. Sometimes, however, anemia can persist in HIV-
chronically-infected patients, even after HIV replication 
was suppressed with cART, and it has been associated 
with elevated levels of IL-6, CRP and D-dimer [3] and 
with monocyte activation [25]. This condition is consid-
ered as anemia of chronic inflammation.
This study was designed to characterize iron homeosta-
sis and inflammation in relation to anemia at HIV diag-
nosis, and after the decline of virus titers in plasma due 
to cART introduction in a group of HIV-infected patients 
with mild anemia and  CD4+ cells > 200/mm3.
Methods
Patients
We conducted a retrospective cohort study. Patients were 
recruited from the HIV-infected patients of the Stand-
ardized Management of Antiretroviral Therapy Cohort 
(MASTER cohort) followed in the University Depart-
ment of Infectious and Tropical Diseases of the Univer-
sity of Brescia [26]. Anemia was defined based on WHO 
hemoglobin cutoffs [27]. We retrospectively selected all 
Caucasian HIV-infected male patients with the following 
characteristics: (i) hemoglobin (Hb) value between 9.5 
and 13 g/dl and  CD4+ cell count > 200/mm3 before cART 
initiation (T0); (ii) plasma HIV RNA < 37 copies/ml after 
6 months of first cART; (iii) maintained cART response 
(plasma HIV RNA  <  37 copies/ml at 6 and 12  months 
of stable cART) (T1 = 12 months); (iv) available plasma 
samples either at T0 and T1, stored at − 80 °C. Patients 
were classified into 2 groups: group A, with Hb < 13 g/dl 
at T0 and Hb > 13 g/dl at T1 and group B, with Hb < 13 g/
dl both at T0 and T1. Exclusion criteria were: (i) severe 
anemia (Hb < 8 g/dl), (ii) acute HIV-infection, (iii) severe 
concomitant diseases (opportunistic infections, cancer) 
at T0 or during the study period, congenital disorders of 
Hb synthesis, (iv) also female gender was a criterion for 
exclusion to reduce the confounding of iron loss.
Assessment of inflammatory and iron metabolism markers
Plasma samples at T0 and T1 were tested for levels of 
predefined inflammatory and iron homeostasis mark-
ers. Serum C reactive protein (CRP), iron and transferrin 
(TF) were quantified using the Dimension Vista 5 Sie-
mens automated analyzer, using commercially available 
reagents (Siemens Healthcare GmbH, Erlangen, Ger-
many). The percentage of transferrin saturation (%TS) 
was calculated on the basis of iron and TF values. Serum 
ferritin levels were measured using the Abbott Architect 
automated analyzer with the Abbott Architect Ferritin 
Assay (Abbott Laboratories, Chicago, IL, US). Hb lev-
els were determined using the Beckman Coulter Unicell 
DxH800analyzer (Beckman Coulter, Brea, CA, US). IL-2, 
IL-3, IL-4, IL-5, IL-7, IL-8, IL-10, IL-18, interferon-γ 
(IFN-γ), tumor necrosis factor-α (TNF-α), tumor necro-
sis factor-γ (TNF-γ), Macrophage inflammatory protein-
1-α (MIP-1-α), macrophage inflammatory protein-1-β 
(MIP-1-β), monocyte chemotactic protein 1 (MCP-1) 
and granulocyte–macrophage colony-stimulating factor 
(GM-CSF) serum levels were measured using the Myriad 
RBM Cytokine MAP A panel (Myriad RBM, Austin TX, 
US). Commercial ELISA kits were used to quantify serum 
levels of IL-6, IL-22 (Cloud-Clone Corporation, Houston, 
TX, USA) and hepcidin (DRG Diagnostic, Marburg, Ger-
many), according to the manufacturer’s protocols.
Statistical analysis
Student’s t test (for age) and χ2 test (for HCV coinfec-
tion, tobacco and intravenous drug use) were used to 
compare patients of group A and B for demographic and 
epidemiological characteristics. Quantitative variables 
were compared at baseline (T0) and 12 months later (T1) 
using Wilcoxon rank sum tests for paired samples in all 
samples (n = 18), group A (n = 10) and group B (n = 8). 
The same variables were analyzed comparing group A vs 
group B, both at T0 and T1, using Wilcoxon rank sum 
tests for independent samples. p  <  0.05 was considered 
to be statistically significant. Pearson correlation coeffi-
cients were computed to determine possible associations 
between biomarkers, resulting in a symmetric correla-
tion matrix (Additional file  1) (highlighted in bold the 
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coefficients major of 0.7 in absolute value, when p values 
are < 0.05). In heatmap graphical representation, values 
contained in a datamatrix, previously standardized with 
mean 0 and standard deviation 1, were represented with 
colors. In detail, low (negative), mean (near to 0), and 
high (positive) values were represented with blue, yellow 
and red, respectively. Heatmaps place similar values near 
each other according to the clustering algorithm used in 
the analysis which is based on the Euclidean distance. 
Hence, we obtained two dendrograms which were added 
to the heatmap on x- and y-axis, respectively.
Ethics statement
The study was conducted in accordance with the Dec-
laration of Helsinki and the principles of Good Clinical 
Practice. All patients provided written informed consent 
to include their clinical and biological data in the MAS-
TER database [22]. All patients signed the informed con-
sent for archiving a plasma sample at baseline and every 
6 months for scientific purposes. The study was approved 
by the Ethical Committee of the Civic Hospital of Brescia 
(Coordinating Centre) and of all the participant Centers 
[26].
Results
The studied population consisted of 18 HIV-1-infected 
treatment-naïve patients with mild anemia (Hb value 
between 9.5 and 13 g/dl) at time of initiating cART (T0). 
After cART, all patients had plasma HIV-1 RNA levels 
consistently < 37 copies/ml, as measured by commercial 
assays at 6, 9 and 12 months of treatment. Ten patients 
increased Hb values above 13  g/dl at T1 and then they 
were retrospectively included in group A (median Hb val-
ues: T0 = 12.70 g/dl; T1 = 14.25 g/dl; p = 0.0020), while 8 
patients remained anemic at T1 and were retrospectively 
included in group B (median Hb values: T0 =  11.85  g/
dl; T1 =  11.95  g/dl; p =  0.3828). The characteristics of 
the population are shown in Table 1. Among patients of 
group A, none used intravenous drugs or had hepatitis C 
virus (HCV) chronic infection and only 30% were habit-
ual smokers. Among patients of group B, HCV chronic 
infection was present in 62.5% (5 out 8) of patients, but 
any HCV coinfected patient was under HCV treatment, 
75% (6 out 8) had acquired HIV-infection by intravenous 
drug use and 100% were smokers.
As expected, cART improved  CD4+ cell count, and 
 CD4+/CD8+ ratio (T0 vs T1 median values). This effect 
was statistically significant for patients from group A, but 
not for those from group B (Table 2).
Iron metabolism
Patients of group A, who resolved anemia with cART, 
had mild iron deficiency at T0, but a trend to the increase 
of serum iron levels with anti-retroviral therapy was 
observed (from 54  mg/dl at T0 up to 71  mg/dl at T1). 
Conversely, in patients of group B, plasma iron levels 
were within the reference values (>  60  mg/dl for adult 
male), despite of anemia and significantly higher than 
in patients of group A at T0 (85.5  mg/dl vs 54  mg/dl; 
p = 0.0455) and iron values did not significantly changed 
with cART (T0 =  85.5  mg  dl and at T1 =  70.5  mg/dl, 
p = 0.3828). Further, while TF levels did not significantly 
change in both groups with cART, patients of group A 
had higher TF values than patients of group B at both 
times, although the difference was not statistically sig-
nificant (203 mg/dl vs 184.5 mg/dl at T0; p = 0.3154; and 
215.5 mg/dl vs 184.5 mg/dl at T1; p = 0.0619). The %TS 
was significantly lower in patients of group A than in 
patients of group B at T0 (21.41% vs 34.28%; p = 0.0085), 
but the difference disappeared with cART (29.83% vs 
30.02%; p = 0.6334) (Table 2).
Inflammation markers
In general, cART decreased values of several inflam-
matory markers in all patients. But, while in patients 
of group A, the decrease was significant only for fer-
ritin (192.5  ng/ml vs 80  ng/ml; p =  0.0488), in patients 
of group B it was significant for IL-18 (428  pg/ml vs 
348 pg/ml; p = 0.0391) and MCP-1 (166 pg/ml vs 131 pg/
ml; p  =  0.0360). Further, we found that all inflamma-
tory markers were always higher in patients of group B 
than in patients of group A, although reaching statistical 
significance only for IL-8 values at T1 (16 vs 2.9 pg/ml; 
p = 0.017) (Table 2).
Table 1 Demografic and epidemiological characteristics of patients
Student’s t test was used to compare age and χ2 test to compare HCV coinfection, tobacco and intravenous drug use
Total (n = 18) Group A (n = 10) Group B (n = 8) p value
Age (years) (mean ± SD) 42.8 ± 8.6 45.6 ± 9.6 39.3 ± 6.0 0.1221
HCV infected (n%) 5 (27.8%) 0 5 (62.5%) 0.0033
Smokers (n%) 11 (61.1%) 3 (30%) 8 (100%) 0.0025
Intravenous drug users 6 (33.3%) 0 6 (75%) 0.0019
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Only in patients of group B, we observed that cART 
increased MIP-1-β and hepcidin values, although the 
increase did not reach the statistical significance (176 pg/
ml vs 192  pg/ml; p  =  0.9453; and 1.84 vs 2.46  ng/ml; 
p  =  0.5469, respectively). Hepcidin and IL-6 levels 
did not show significant differences between groups, 
but a trend toward higher levels in group A vs group B 
were observed (hepcidin at T0: 4.41  ng/ml vs 1.84  ng/
ml; p =  0.2301; hepcidin at T1: 2.71  ng/ml vs 2.46  ng/
ml; p  =  0.3740; IL-6 at T0: 6.11  pg/ml vs 4.52  pg/
ml; p  =  0.2743; IL-6 at T1: 4.97  pg/ml vs 4.23  pg/ml; 
p  =  0.2133). Interestingly, the ratio hepcidin/ferritin 
increased with cART in patients of group A (0.03 vs 0.05; 
p = 0.0645), but decreased in patients of group B (0.02 vs 
0.01; p = 0.3828) (Table 2).
Serum levels of some markers were below the detec-
tion limit of the assays (CRP, IL-2, IL-3, IL-4, IL-5, IL-7, 
GM-CSF, TNF-β and IFN-γ) in most patients and were 
not included in the study, while for most samples IL-10, 
TNF-α and MIP-1-α were detectable and interestingly 
decreased below the detection limit at T1 only in patients 
from group A (Fig. 1).
Fig. 1 Biomarker levels in HIV‑infected patients. Serum levels of IL‑10, tumor necrosis factor α (TNF‑α) and hepcidin in HIV‑infected patients at 
baseline (T0) and after 12 months (T1) of combination anti‑retroviral therapy (cART) in group A, group B and all patients. Wilcoxon rank sum test 
for independent samples was used to compare median values of patients of group A vs patients of group B. Outliers were identified by means of 
circles. p values are also reported
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Correlation matrix and heatmaps representation
We did not found linear relationship between Hb or iron 
levels when all 18 patients were considered together with 
hepcidin, any marker of inflammation,  CD4+,  CD8+ cell 
count or  CD4+/CD8+ ratio (Additional file  1). We also 
performed the heatmap analysis to identify possible clus-
ters or pathways among variables (Fig.  2). Interestingly, 
only in group B, iron was clustered among inflammatory 
markers both at T0 and T1, but not with Hb, TF, hepci-
din and IL-6.
Discussion
Here, we describe that baseline mild anemia in HIV-
infected patients cannot always be resolved with dura-
ble efficient cART. In general, cART decreased values 
of inflammatory markers and ameliorated iron metabo-
lism in all patients. But HIV-infected patients with ane-
mia that is resolved with cART had lower levels of IL-8, 
IL-18, IL-22, MIP-1-β and MCP-1 and higher IL-6 and 
hepcidin levels than patients with persistent anemia, 
either at T0 and T1. On the other hand, HIV-infected 
Fig. 2 Heatmap analysis. Heatmap analysis on biomarker levels relative to patients in group A and in group B
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patients with anemia that is not resolved with cART are 
frequently coinfected with HCV (62%), and at baseline 
they have higher values of iron, %TS and IL-18 and a 
trend toward lower levels of hepcidin and IL-6, compared 
to those patients in whom anemia was resolved by cART. 
Furthermore, patients with persistent anemia had minor 
immune recovery.
Several studies in HIV-infected patients have found an 
inverse association between hepcidin and absolute  CD4+ 
cell count [17, 21], suggesting that elevated hepcidin may 
be ascribed to advanced disease stage and elevated lev-
els of inflammation. Most recently, Rosado-Sanchez et al. 
[28] observed that high levels of IL-6, CRP, high  CD4+ 
cell turnover and regulatory T cell (Treg) frequency 
are already present prior to initiation of cART in HIV-
infected patients with poorer  CD4+ cell recovery, sug-
gesting a role of inflammation on  CD4+ cell homeostasis. 
In HIV-infected patients the chronic exposure to other 
antigens or pathogens, like cytomegalovirus (CMV) or 
HCV, may also contribute to persistent inflammation 
or immune activation [29–31] and clinical events [32, 
33]. In cART-treated HIV-infection with minimal  CD4+ 
cell defects, HCV seems not to be associated with cel-
lular immune activation, but it may rather contribute to 
immune exhaustion [30]. In our study that includes HIV-
infected patients from an Italian cohort with mild anemia 
and median  CD4+ cells > 400/mm3 at baseline, cART sig-
nificantly increased  CD4+ cell count in patients of group 
A (none HIV/HCV infected), but not in group B (62% of 
them was HIV/HCV coinfected).
cART initiation consistently leads to decrease in most 
systemic inflammatory markers, T cell indices and mono-
cyte activation, albeit rarely to levels comparable to those 
of HIV-uninfected individuals [34]. This chronic state of 
inflammation/immune activation, that it is established 
during HIV-infection as a result of the complex interac-
tions between viral and host factors, may be associated to 
clinical consequences despite of efficient cART. Increased 
values of IL-18 have been associated with clinical cART 
failure in HIV-infected patients [35] and high level of 
IL-8 has been associated with lower number of  CD4+ 
cell count and HIV disease progression in children [36]. 
Patients of group B in our study, who did not recover 
from anemia, had indeed higher levels of IL-8 and IL-18.
Many potential mechanisms for this chronic inflam-
matory state have been proposed: HIV itself, translo-
cated microbial products, other chronic concomitant 
pathogens, including CMV and HCV, and lipids [37, 38]. 
Despite of cART success, HIV/HCV coinfected patients 
have poorer prognosis and more rapid progression of 
liver disease, probably due to the excessive inflammation/
immune activation in HIV/HCV coinfection, compared 
to either HIV or HCV mono-infection [39, 40].
Interactions between HIV and HCV in respect to 
inflammation and iron metabolism are complex and 
poorly known. Distinct patterns of iron homeostasis 
occur during different viral infections. Acute HIV infec-
tion causes a decrease of serum iron that is accompanied 
by increase in hepcidin, CRP, IL-10, IL-18 and TNF-α. 
Levels remained elevated in cART treated patients, in 
spite of undetectable HIV replication and Hb normali-
zation. Interestingly, hepcidin up-regulation or hypofer-
remia were not evidenced during acute HCV or HBV 
infection [19]. In contrast, a recent study in chronically 
HCV-infected patients has showed that liver disease 
activity has a negative impact on erythropoiesis with 
compensatory higher but blunted EPO responses [41].
Data are emerging about differences between HIV 
monoinfected and HIV/HCV coinfected patients in lev-
els of markers of inflammation and iron metabolism dys-
regulation. In  vitro co-stimulation of HepG2 cells with 
HCV-E2 and HIV-gp120 proteins induces a potent pro-
inflammatory response with the production of IL-8 [42] 
and it is suggested that in vivo IL-8 could be responsible 
for the local inflammatory changes that induce fibrosis 
in HCV-infected patients and the severe liver damage 
observed in HCV/HIV co-infected patients [43]. Higher 
plasma levels of IL-6, IL-8, IL-18 and MIP-1-β have been 
recently observed in HIV/HCV coinfected patients than 
in both monoinfections. It has been hypothesized that 
high levels of some of these cytokines could be respon-
sible for the increased incidence and progression of 
inflammatory illness in HIV/HCV chronically coin-
fected patients, even in patients on cART with undetect-
able HIV RNA [30, 44]. Here, we observed that cART 
decreased IL-8, IL-18 and MCP-1 in all patients, however 
their levels remained higher in group B than in group A. 
cART has been described to induce slow fibrosis progres-
sion in HIV/HCV-coinfected patients with successful 
HIV suppression, but progression remains accelerated 
compared with HCV-monoinfected patients [45]. Indeed, 
recent studies have shown that hepcidin levels is reduced 
in both liver and serum of patients with HCV infection, 
which may contribute to pathological liver iron storage 
and elevated serum ferritin and iron levels [46–48].
We found that IL-8 level was higher in group B (that 
included most of patients with chronic HCV infection) 
than in group A and, although cART decreased its level 
in both groups, it remained significantly higher in group 
B. These patients were anemic with normal values of 
serum iron and %TS, significantly higher than those of 
patients of group A at T0, and, despite the control of HIV 
replication with cART for more than 6 months.
Our study has some limitations. First, the study was 
performed in a limited number of patients. Second, 
we do not know if there were differences in time of 
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infection between the two groups, despite the fact that 
both groups showed similar time from diagnosis and the 
mean of  CD4+ cells between groups was similar. Third, 
the present study was not designed to analyze differences 
in inflammatory cytokine or iron marker levels between 
HIV/HCV and HIV monoinfected patients, but, casu-
ally, most patients of group B were HIV/HCV infected 
[39, 49]. The longitudinal design of this study, in con-
trast with other studies comparing several groups in a 
cross-sectional way, confers it an important strength. 
The participants in this cohort had sustained virologic 
suppression, below the limits of detection of commercial 
assays, mitigating the potential effects of virologic failure 
or transient viremia on measures of anemia or inflamma-
tion, that might be observed in less-adherent individuals. 
Another strength of the present study is the high number 
of inflammatory markers tested.
Conclusions
Additional inflammation other than HIV-mediated can 
be responsible for the persistent mild chronic anemia 
and for the slower  CD4+ and  CD4+/CD8+ increase in 
patients with sustained plasmatic HIV suppression by 
cART. Understanding the mechanisms that mediate the 
inflammation/immune activation in HIV with suppres-
sive cART is a challenging issue. Profiling the cytokines 
will plausibly enable identification of factors that could 
complement the information from viral load and  CD4+ 
cell counts in the management of the disease and thera-
peutic interventions.
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